3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation

Diabetes is one of the fastest-growing metabolic disorders, nearly doubling the number of patients each year. There are different treatment approaches available for the management of diabetes, which lacks due to their side effects. The inhibition of enzymes involved in the metabolism of complex poly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2024-02, Vol.266, p.116139-116139, Article 116139
Hauptverfasser: Singh, Gurpreet, Singh, Rajveer, Monga, Vikramdeep, Mehan, Sidharth
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 116139
container_issue
container_start_page 116139
container_title European journal of medicinal chemistry
container_volume 266
creator Singh, Gurpreet
Singh, Rajveer
Monga, Vikramdeep
Mehan, Sidharth
description Diabetes is one of the fastest-growing metabolic disorders, nearly doubling the number of patients each year. There are different treatment approaches available for the management of diabetes, which lacks due to their side effects. The inhibition of enzymes involved in the metabolism of complex polysaccharides to monosaccharides has proven beneficial in patients with type 2 diabetes mellitus. Two enzymes, α-amylase and α-glucosidase, have emerged as potential drug targets and are widely explored for drug development against type 2 diabetes mellitus. In this context, thiazolidine-2,4-diones (TZDs) have emerged as potential drug candidates for developing newer molecules against α-amylase and α-glucosidase. Nineteen TZD-hybrids were synthesized and evaluated in vitro α-amylase and α-glucosidase inhibitory activity. The compounds 7i, 7k, and 7p have emerged as the best dual inhibitors with IC50 of 10.33 ± 0.11–20.94 ± 0.76 μM and 10.19 ± 0.25–24.07 ± 1.56 μM against α-glucosidase and α-amylase, respectively. The derivatives had good anti-oxidant activity, displaying IC50 = 14.95 ± 0.65–23.27 ± 0.99 μM. The compounds 7k and 7p showed the best inhibition of reactive oxygen species in the PNAC-1 cells. The molecules exhibit good binding within the active site of α-amylase (PDB id: 1B2Y) and α-glucosidase (PDB id: 3W37), displaying binding energies of −7.5 to −10.7 kcal/mol and −7.4 to −10.3 kcal/mol, respectively. Further, the compounds were nontoxic (LD50 = 500–1311 mg/kg) and possessed good GI absorption. The compounds 7i, 7k, and 7p were evaluated in vivo antidiabetic activity in an STZ-induced diabetic model in Wistar rats. The compound 7p emerged as the best compound in the in vivo studies; however, the activity was lesser than that of the standard drug pioglitazone. [Display omitted] •3,5-disubstituted-thiazoidine-2,4-diones were synthesized and characterized.•α-amylase, α-glucosidase, antioxidant and cytotoxicity was assessed for the synthesized compounds.•Docking and in silico drug likeness studies were performed.•Antidiabetic effect of compounds 7i, 7 k and 7p was established using STZ-induced diabetic model in Wistar rats.•Compound 7p emerged as best anti-diabetic agents.
doi_str_mv 10.1016/j.ejmech.2024.116139
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2917865634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523424000199</els_id><sourcerecordid>2917865634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-415430233844ab3d87be96ce3cf8b9fe48cca4869ea44589170cdbd9700a0a803</originalsourceid><addsrcrecordid>eNp9kN9rFDEQx4Mo9qz-ByL76MPlzK_NZX0QpFVbKPjSPodsMtebYy9bk-zC6T9vylYfCwMzMN_vfJkPIe8523DG9afDBg5H8PuNYEJtONdcdi_Iim-1oVK06iVZMSEkbYVUZ-RNzgfGWKsZe03OpBGt6Ey3In_kuqWXmKc-FyxTgUDLHt3vccCAEahYKxpwjNDsT33CkBtXK5a6dT0U9I27h1jy5-YSMt7HdZNPsezrnNcNRjpjSWM1hOY6NjPOYwOzGyZX6s235NXODRnePfVzcvf92-3FFb35-eP64usN9ULoQhVvlWRCSqOU62Uw2x467UH6nem7HSjjvVNGd-CUak3Ht8yHPnRbxhxzhslz8nG5-5DGXxPkYo-YPQyDizBO2YpqMbrVUlWpWqQ-jTkn2NmHhEeXTpYz-4jdHuyC3T5itwv2avvwlDD1Rwj_Tf84V8GXRQD1zxkh2ewRooeACXyxYcTnE_4CPNmVrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2917865634</pqid></control><display><type>article</type><title>3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation</title><source>Elsevier ScienceDirect Journals</source><creator>Singh, Gurpreet ; Singh, Rajveer ; Monga, Vikramdeep ; Mehan, Sidharth</creator><creatorcontrib>Singh, Gurpreet ; Singh, Rajveer ; Monga, Vikramdeep ; Mehan, Sidharth</creatorcontrib><description>Diabetes is one of the fastest-growing metabolic disorders, nearly doubling the number of patients each year. There are different treatment approaches available for the management of diabetes, which lacks due to their side effects. The inhibition of enzymes involved in the metabolism of complex polysaccharides to monosaccharides has proven beneficial in patients with type 2 diabetes mellitus. Two enzymes, α-amylase and α-glucosidase, have emerged as potential drug targets and are widely explored for drug development against type 2 diabetes mellitus. In this context, thiazolidine-2,4-diones (TZDs) have emerged as potential drug candidates for developing newer molecules against α-amylase and α-glucosidase. Nineteen TZD-hybrids were synthesized and evaluated in vitro α-amylase and α-glucosidase inhibitory activity. The compounds 7i, 7k, and 7p have emerged as the best dual inhibitors with IC50 of 10.33 ± 0.11–20.94 ± 0.76 μM and 10.19 ± 0.25–24.07 ± 1.56 μM against α-glucosidase and α-amylase, respectively. The derivatives had good anti-oxidant activity, displaying IC50 = 14.95 ± 0.65–23.27 ± 0.99 μM. The compounds 7k and 7p showed the best inhibition of reactive oxygen species in the PNAC-1 cells. The molecules exhibit good binding within the active site of α-amylase (PDB id: 1B2Y) and α-glucosidase (PDB id: 3W37), displaying binding energies of −7.5 to −10.7 kcal/mol and −7.4 to −10.3 kcal/mol, respectively. Further, the compounds were nontoxic (LD50 = 500–1311 mg/kg) and possessed good GI absorption. The compounds 7i, 7k, and 7p were evaluated in vivo antidiabetic activity in an STZ-induced diabetic model in Wistar rats. The compound 7p emerged as the best compound in the in vivo studies; however, the activity was lesser than that of the standard drug pioglitazone. [Display omitted] •3,5-disubstituted-thiazoidine-2,4-diones were synthesized and characterized.•α-amylase, α-glucosidase, antioxidant and cytotoxicity was assessed for the synthesized compounds.•Docking and in silico drug likeness studies were performed.•Antidiabetic effect of compounds 7i, 7 k and 7p was established using STZ-induced diabetic model in Wistar rats.•Compound 7p emerged as best anti-diabetic agents.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2024.116139</identifier><identifier>PMID: 38252989</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Acarbose ; Diabetes ; In-vivo antidiabetic evaluation ; Knoevenagel ; Molecular docking ; Thiazolidine-2,4-dione ; Wistar rats ; α-amylase ; α-glucosidase</subject><ispartof>European journal of medicinal chemistry, 2024-02, Vol.266, p.116139-116139, Article 116139</ispartof><rights>2024 Elsevier Masson SAS</rights><rights>Copyright © 2024 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c226t-415430233844ab3d87be96ce3cf8b9fe48cca4869ea44589170cdbd9700a0a803</cites><orcidid>0000-0003-0034-835X ; 0000-0003-4004-6241</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523424000199$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38252989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Gurpreet</creatorcontrib><creatorcontrib>Singh, Rajveer</creatorcontrib><creatorcontrib>Monga, Vikramdeep</creatorcontrib><creatorcontrib>Mehan, Sidharth</creatorcontrib><title>3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Diabetes is one of the fastest-growing metabolic disorders, nearly doubling the number of patients each year. There are different treatment approaches available for the management of diabetes, which lacks due to their side effects. The inhibition of enzymes involved in the metabolism of complex polysaccharides to monosaccharides has proven beneficial in patients with type 2 diabetes mellitus. Two enzymes, α-amylase and α-glucosidase, have emerged as potential drug targets and are widely explored for drug development against type 2 diabetes mellitus. In this context, thiazolidine-2,4-diones (TZDs) have emerged as potential drug candidates for developing newer molecules against α-amylase and α-glucosidase. Nineteen TZD-hybrids were synthesized and evaluated in vitro α-amylase and α-glucosidase inhibitory activity. The compounds 7i, 7k, and 7p have emerged as the best dual inhibitors with IC50 of 10.33 ± 0.11–20.94 ± 0.76 μM and 10.19 ± 0.25–24.07 ± 1.56 μM against α-glucosidase and α-amylase, respectively. The derivatives had good anti-oxidant activity, displaying IC50 = 14.95 ± 0.65–23.27 ± 0.99 μM. The compounds 7k and 7p showed the best inhibition of reactive oxygen species in the PNAC-1 cells. The molecules exhibit good binding within the active site of α-amylase (PDB id: 1B2Y) and α-glucosidase (PDB id: 3W37), displaying binding energies of −7.5 to −10.7 kcal/mol and −7.4 to −10.3 kcal/mol, respectively. Further, the compounds were nontoxic (LD50 = 500–1311 mg/kg) and possessed good GI absorption. The compounds 7i, 7k, and 7p were evaluated in vivo antidiabetic activity in an STZ-induced diabetic model in Wistar rats. The compound 7p emerged as the best compound in the in vivo studies; however, the activity was lesser than that of the standard drug pioglitazone. [Display omitted] •3,5-disubstituted-thiazoidine-2,4-diones were synthesized and characterized.•α-amylase, α-glucosidase, antioxidant and cytotoxicity was assessed for the synthesized compounds.•Docking and in silico drug likeness studies were performed.•Antidiabetic effect of compounds 7i, 7 k and 7p was established using STZ-induced diabetic model in Wistar rats.•Compound 7p emerged as best anti-diabetic agents.</description><subject>Acarbose</subject><subject>Diabetes</subject><subject>In-vivo antidiabetic evaluation</subject><subject>Knoevenagel</subject><subject>Molecular docking</subject><subject>Thiazolidine-2,4-dione</subject><subject>Wistar rats</subject><subject>α-amylase</subject><subject>α-glucosidase</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kN9rFDEQx4Mo9qz-ByL76MPlzK_NZX0QpFVbKPjSPodsMtebYy9bk-zC6T9vylYfCwMzMN_vfJkPIe8523DG9afDBg5H8PuNYEJtONdcdi_Iim-1oVK06iVZMSEkbYVUZ-RNzgfGWKsZe03OpBGt6Ey3In_kuqWXmKc-FyxTgUDLHt3vccCAEahYKxpwjNDsT33CkBtXK5a6dT0U9I27h1jy5-YSMt7HdZNPsezrnNcNRjpjSWM1hOY6NjPOYwOzGyZX6s235NXODRnePfVzcvf92-3FFb35-eP64usN9ULoQhVvlWRCSqOU62Uw2x467UH6nem7HSjjvVNGd-CUak3Ht8yHPnRbxhxzhslz8nG5-5DGXxPkYo-YPQyDizBO2YpqMbrVUlWpWqQ-jTkn2NmHhEeXTpYz-4jdHuyC3T5itwv2avvwlDD1Rwj_Tf84V8GXRQD1zxkh2ewRooeACXyxYcTnE_4CPNmVrA</recordid><startdate>20240215</startdate><enddate>20240215</enddate><creator>Singh, Gurpreet</creator><creator>Singh, Rajveer</creator><creator>Monga, Vikramdeep</creator><creator>Mehan, Sidharth</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0034-835X</orcidid><orcidid>https://orcid.org/0000-0003-4004-6241</orcidid></search><sort><creationdate>20240215</creationdate><title>3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation</title><author>Singh, Gurpreet ; Singh, Rajveer ; Monga, Vikramdeep ; Mehan, Sidharth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-415430233844ab3d87be96ce3cf8b9fe48cca4869ea44589170cdbd9700a0a803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acarbose</topic><topic>Diabetes</topic><topic>In-vivo antidiabetic evaluation</topic><topic>Knoevenagel</topic><topic>Molecular docking</topic><topic>Thiazolidine-2,4-dione</topic><topic>Wistar rats</topic><topic>α-amylase</topic><topic>α-glucosidase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Gurpreet</creatorcontrib><creatorcontrib>Singh, Rajveer</creatorcontrib><creatorcontrib>Monga, Vikramdeep</creatorcontrib><creatorcontrib>Mehan, Sidharth</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Gurpreet</au><au>Singh, Rajveer</au><au>Monga, Vikramdeep</au><au>Mehan, Sidharth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2024-02-15</date><risdate>2024</risdate><volume>266</volume><spage>116139</spage><epage>116139</epage><pages>116139-116139</pages><artnum>116139</artnum><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Diabetes is one of the fastest-growing metabolic disorders, nearly doubling the number of patients each year. There are different treatment approaches available for the management of diabetes, which lacks due to their side effects. The inhibition of enzymes involved in the metabolism of complex polysaccharides to monosaccharides has proven beneficial in patients with type 2 diabetes mellitus. Two enzymes, α-amylase and α-glucosidase, have emerged as potential drug targets and are widely explored for drug development against type 2 diabetes mellitus. In this context, thiazolidine-2,4-diones (TZDs) have emerged as potential drug candidates for developing newer molecules against α-amylase and α-glucosidase. Nineteen TZD-hybrids were synthesized and evaluated in vitro α-amylase and α-glucosidase inhibitory activity. The compounds 7i, 7k, and 7p have emerged as the best dual inhibitors with IC50 of 10.33 ± 0.11–20.94 ± 0.76 μM and 10.19 ± 0.25–24.07 ± 1.56 μM against α-glucosidase and α-amylase, respectively. The derivatives had good anti-oxidant activity, displaying IC50 = 14.95 ± 0.65–23.27 ± 0.99 μM. The compounds 7k and 7p showed the best inhibition of reactive oxygen species in the PNAC-1 cells. The molecules exhibit good binding within the active site of α-amylase (PDB id: 1B2Y) and α-glucosidase (PDB id: 3W37), displaying binding energies of −7.5 to −10.7 kcal/mol and −7.4 to −10.3 kcal/mol, respectively. Further, the compounds were nontoxic (LD50 = 500–1311 mg/kg) and possessed good GI absorption. The compounds 7i, 7k, and 7p were evaluated in vivo antidiabetic activity in an STZ-induced diabetic model in Wistar rats. The compound 7p emerged as the best compound in the in vivo studies; however, the activity was lesser than that of the standard drug pioglitazone. [Display omitted] •3,5-disubstituted-thiazoidine-2,4-diones were synthesized and characterized.•α-amylase, α-glucosidase, antioxidant and cytotoxicity was assessed for the synthesized compounds.•Docking and in silico drug likeness studies were performed.•Antidiabetic effect of compounds 7i, 7 k and 7p was established using STZ-induced diabetic model in Wistar rats.•Compound 7p emerged as best anti-diabetic agents.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>38252989</pmid><doi>10.1016/j.ejmech.2024.116139</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0034-835X</orcidid><orcidid>https://orcid.org/0000-0003-4004-6241</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2024-02, Vol.266, p.116139-116139, Article 116139
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_2917865634
source Elsevier ScienceDirect Journals
subjects Acarbose
Diabetes
In-vivo antidiabetic evaluation
Knoevenagel
Molecular docking
Thiazolidine-2,4-dione
Wistar rats
α-amylase
α-glucosidase
title 3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=3,5-Disubstituted-thiazolidine-2,4-dione%20hybrids%20as%20antidiabetic%20agents:%20Design,%20synthesis,%20in-vitro%20and%20In%20vivo%20evaluation&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Singh,%20Gurpreet&rft.date=2024-02-15&rft.volume=266&rft.spage=116139&rft.epage=116139&rft.pages=116139-116139&rft.artnum=116139&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2024.116139&rft_dat=%3Cproquest_cross%3E2917865634%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2917865634&rft_id=info:pmid/38252989&rft_els_id=S0223523424000199&rfr_iscdi=true